Title

The date should reflect the date the final report is submitted to the Department.

 Month Year

 MSAC application no. XXXX

 Critique report

 Prepared by Assessment Group

# Version Control

## Document History

| **Version Number** | **Date Changed** | **Author** | **Reason for Change** |
| --- | --- | --- | --- |
| 1.1 | 18-Feb-2016 | Sean McCandless | Version control introduced |
| 2.1 | 9-Mar-2016 | Sean McCandless | Added Alt text to Version Control tablesRenamed and printed document to Portable Document Format in preparation for publishing Online. |
| 3.1 | 28-Jul-2017 | Sean McCandless | Document converted to (.docx) format for web publishing purposes and table on front page removed for accessibility purposes. |

## Document Approval

| **Version Number** | **Date Changed** | **Author** | **Reason for Change** |
| --- | --- | --- | --- |
| 2.0 | 18-Feb-2016 | Sean McCandless | Version control introduced |
| 3.0 | 9-Mar-2016 | Sean McCandless | Document Released |
| 4.0 | 28-Jul-2016 | Sean McCandless | Document Released |
|  |  |  |  |

Note to reader: this document contains hidden text. Please click on the show/hide icon ¶ in the Home menu so that you can see the instructions and suggestions for filling in this template. Delete this text prior to finalisation of the document.

This template is meant to be used when critiquing a submission-based assessment (SBA) of a therapeutic service.

This text is written in hidden text. The **hidden (red) text** provides instructions or suggestions for completing the different sections of the template. *Hidden text styles can be selected from the Font menu.* All hidden text has a dotted underline under it. When you have finished addressing the hidden text in this template, please remember to delete it and change the style to normal (non-hidden) text. If you don’t do this you will have large blank areas in your document.

This template is written in Microsoft Word 2010 – this is because some people may not yet be using Word 2013.

This document is a **template file (ie .dotx**). This means if you double-click on the file it will open as a new Word document but it will contain the same formatting (fonts, heading styles) and structural elements as included in the template. This will help with maintaining consistency in the presentation and data elements across all critiques of SBAs.

Any **text written in black** in the template **must** be included in the report *unless* the text is surrounded by this type of parentheses < >. These parentheses indicate that the text is optional or its inclusion will depend on a specific circumstance. Please remember to *remove* the < >, if you decide to *include* the optional text in the report. Please remember to delete the < > *and* the text it surrounds if you decide to *exclude* the optional text from the report.

The critique template is structured into Sections A, B, C, D, E and F in order to align with the MSAC *Technical Guidelines – Therapeutic,* as well as the template for writing SBAs.

When writing your critique of the statements made in the SBA, you should **use the “Comment” style** which ensures the text is in italics ie *all comments should be written in italics.*

Following completion of the report, the hidden text on this page and throughout the document – as well as the next page break - should be deleted.

## Contents

[Executive Summary iv](#_Toc428263137)

[Alignment with agreed PICO Confirmation iv](#_Toc428263138)

[Proposed Medical Service iv](#_Toc428263139)

[Proposal for Public Funding iv](#_Toc428263140)

[Population iv](#_Toc428263141)

[Comparator Details iv](#_Toc428263142)

[Clinical Management Algorithm(s) iv](#_Toc428263143)

[Key Differences in the Delivery of the Proposed Medical Service and the Main Comparator iv](#_Toc428263144)

[Clinical Claim iv](#_Toc428263145)

[Approach Taken to the Evidence Assessment iv](#_Toc428263146)

[Characteristics of the Evidence Base iv](#_Toc428263147)

[Comparative Safety iv](#_Toc428263148)

[Comparative Effectiveness iv](#_Toc428263149)

[Translation Issues iv](#_Toc428263150)

[Economic Evaluation iv](#_Toc428263151)

[Estimated Extent of Use and Financial Implications iv](#_Toc428263152)

[Consumer impact summary iv](#_Toc428263153)

[<Other Relevant Considerations> iv](#_Toc428263154)

[Section A Context 4](#_Toc428263155)

[A.1. Items in the agreed PICO Confirmation 4](#_Toc428263156)

[A.2. Proposed Medical Service 4](#_Toc428263157)

[<Marketing status of device / technology> 4](#_Toc428263158)

[<Other Indications> 4](#_Toc428263159)

[<Current funding arrangements> 4](#_Toc428263160)

[A.3. Proposal for Public Funding 4](#_Toc428263161)

[A.4. Proposed population 4](#_Toc428263162)

[A.5. Comparator Details 4](#_Toc428263163)

[A.6. Clinical management algorithm(s) 4](#_Toc428263164)

[Prerequisites 4](#_Toc428263165)

[Co-administered and substituted interventions 4](#_Toc428263166)

[A.7. Key Differences in the Delivery of the Proposed Medical Service and the Main Comparator 4](#_Toc428263167)

[A.8. Clinical Claim 4](#_Toc428263168)

[A.9. Summary of the PICO 4](#_Toc428263169)

[Section B Clinical Evaluation 4](#_Toc428263170)

[B.1. Literature Sources and Search Strategies 4](#_Toc428263171)

[B.2. Results of Literature Search 4](#_Toc428263172)

[Appraisal of the evidence 4](#_Toc428263173)

[B.3. Risk of Bias Assessment 4](#_Toc428263174)

[B.4. Characteristics of the Evidence Base 4](#_Toc428263175)

[B.5. Outcome Measures and Analysis 4](#_Toc428263176)

[B.6. Results of the Systematic Literature review 4](#_Toc428263177)

[Comparative Safety 4](#_Toc428263178)

[<> 4](#_Toc428263179)

[<> 4](#_Toc428263180)

[Comparative Effectiveness 4](#_Toc428263181)

[<> 4](#_Toc428263182)

[<> 4](#_Toc428263183)

[B.7. Extended Assessment of Comparative Harms 4](#_Toc428263184)

[B.8. Interpretation of the Clinical Evidence 4](#_Toc428263185)

[Section C Translation Issues 4](#_Toc428263186)

[C.1. Overview of Economic Evaluation and the Translation Issues that needed to be Addressed 4](#_Toc428263187)

[C.2. Applicability translation issues 4](#_Toc428263188)

[C.3. Extrapolation translation issues 4](#_Toc428263189)

[C.4. Transformation issues 4](#_Toc428263190)

[C.5. Any other translation issues 4](#_Toc428263191)

[C.6. Relationship of each Pre-Modelling Study to the Economic Evaluation 4](#_Toc428263192)

[Section D Economic Evaluation 4](#_Toc428263193)

[D.1. Overview 4](#_Toc428263194)

[D.2. Populations and settings 4](#_Toc428263195)

[D.3. Structure and rationale of the economic evaluation 4](#_Toc428263196)

[Literature review 4](#_Toc428263197)

[Structure of the economic evaluation 4](#_Toc428263198)

[D.4. Inputs to the economic evaluation 4](#_Toc428263199)

[Costs 4](#_Toc428263200)

[Health outcomes 4](#_Toc428263201)

[Transition probabilities used in the economic evaluation 4](#_Toc428263202)

[Utility/disutility values 4](#_Toc428263203)

[Discount rate 4](#_Toc428263204)

[D.5. Results of the Economic Evaluation 4](#_Toc428263205)

[<Incremental costs and effectiveness 4](#_Toc428263206)

[<Stepped economic evaluation 4](#_Toc428263207)

[D.6. Sensitivity analyses 4](#_Toc428263208)

[Section E Financial Implications 4](#_Toc428263209)

[E.1. Justification of the Selection of Sources of Data 4](#_Toc428263210)

[E.2. Use and Costs of <> 4](#_Toc428263211)

[Eligible population for the requested restriction 4](#_Toc428263212)

[Number of patients likely to use the intervention 4](#_Toc428263213)

[<Number of services> 4](#_Toc428263214)

[E.3. Changes in Use and Cost of Other Medical Services 4](#_Toc428263215)

[E.4. Financial Implications for the MBS 4](#_Toc428263216)

[Potential usage outside the requested listing 4](#_Toc428263217)

[E.5. Financial Implications for Government Health Budgets 4](#_Toc428263218)

[The Broader Impact on the MBS 4](#_Toc428263219)

[Other Government Impacts 4](#_Toc428263220)

[State and Territory Government Health Budgets 4](#_Toc428263221)

[E.6. Identification, Estimation and Reduction of Uncertainty 4](#_Toc428263222)

[Section F Other relevant considerations 4](#_Toc428263223)

[References 4](#_Toc428263224)

[Attachment A 4](#_Toc428263225)

[Attachment B 4](#_Toc428263226)

[Attachment C 4](#_Toc428263227)

[Attachment D 4](#_Toc428263228)

[Attachment E 4](#_Toc428263229)

# Executive Summary

## Keep Executive Summary short – 6 pages for a typical technology with one clinical indication.

| Main issues for MSAC consideration |
| --- |
| * *List the key issues that will impact on MSAC decision-making here.*
* *Keep to less than one page.*
* *This should not be a summary of the evidence or critique, but rather, pointing out where critical uncertainties exist.*
 |

**Clearly set out the key aspects and issues that arose during the critique.** For each section in the executive summary, keep the text very brief.

A submission based assessment (SBA) requesting MBS listing of <insert name of intervention> for <insert description of patient population(s)> was received from <insert applicant’s name> by the Department of Health in <insert month & year SBA was received>.

<This application is following a fit-for-purpose pathway, therefore a PICO Confirmation outlining the proposed use of <intervention> in Australian clinical practice was not <presented to/ratified by> the PICO Confirmation Advisory Sub-Committee (PASC).> If this is the case, then Table 1 below does not need to be inserted.

Alignment with agreed PICO Confirmation

<A PICO Confirmation for MSAC Application <number> was approved by the PICO Advisory Sub-Committee (PASC) of MSAC on <insert month, year>. A comparison of the consistency of this SBA with the PASC-approved PICO Confirmation is given in Table 1.>

If there was a PASC-approved PICO Confirmation then the checkbox below should be completed, providing a summary of whether the SBA has followed the PICO Confirmation. If the SBA has provided reasons as to why the PICO Confirmation was not followed, provide a very brief summary in the table of the justification for the change. If you wish to comment on whether the justification is reasonable, do so briefly (in italics – use the table text comment style provided) and expand in the relevant section of the executive summary if needed. If no justification is provided, indicate that the rationale was not given.

Table 1 PICO Confirmation checkbox

| PASC-approved PICO Confirmation Item | Compliance | Change and justification provided in SBA |
| --- | --- | --- |
| Proposed MBS listing | <Yes/No> |  |
| Population / clinical indication | <Yes/No> |  |
| Comparator | <Yes/No> |  |
| Clinical management algorithm | <Yes/No> |  |
| Clinical outcomes assessed | <Yes/No> |  |
| Healthcare resources | <Yes/No> |  |

Source: <Table/Figure, p/pp of SBA> <*Table constructed during the evaluation*>

NA=not applicable; PASC=PICO Confirmation Advisory Sub-Committee

### Proposed Medical Service

Describe the key features of the intervention.

Indicate whether the intervention is currently funded or reimbursed in private or public setting in Australia for the same or another clinical indication.

### Proposal for Public Funding

Provide MBS or other public funding descriptors in the table below. Use the proposed item descriptor as set out in the SBA.

Table 2 Proposed MBS item descriptor

|  |
| --- |
| Category <Insert proposed category no> – <INSERT CATEGORY NAME> |
| <Insert intervention name><Specify any restrictions on use e.g., patient characteristics to be satisfied, limits on frequency of use, limits on who can provide the item, or where it can be provided, etc><Specify any relevant explanatory notes> |
| Fee: <insert proposed MBS fee> |

Source: <Table/Figure>, <p/pp of the SBA>

### Population

Briefly describe the population in whom it is proposed the test should be used, and a summary of the frequency (prevalence and/or incidence) of the population or disease in question.

### Comparator Details

State comparator name or provide a short description.

Comment if not the appropriate comparator and, in a sentence, state why. Recommend an alternative comparator. Is the comparator hospital based or MBS listed?

If this aspect is complex, reference the in-depth discussion in Section A.4. Ensure that any information here is also in Section A.4 (i.e., no new information here).

### Clinical Management Algorithm(s)

Comment on the proposed algorithm – is it realistic? Is it based on an evidence based or consensus-based clinical practice guideline? You might like to refer to the location of the clinical management algorithms in the main body of the report.

*Are there any limitations on how the intervention would be provided or the setting in which the intervention can be provided?*

### Key Differences in the Delivery of the Proposed Medical Service and the Main Comparator

Briefly describe any differences in the delivery/organisation of care associated with the intervention and the main comparator.

Clinical Claim

Provide information about the clinical claim with respect to the proposed intervention, as set out in the PICO Confirmation. If the applicant has not utilised the PASC process to state the clinical claim, please mention this here.

*Comment briefly on whether the claim has been supported by the evidence base.*

### **Approach T**aken to the **E**vidence **A**ssessment

A systematic review of published <and unpublished> literature was undertaken.

Summarise databases searched and/or time period, key study selection criteria (PICO), methods for selecting studies and critical appraisal methods.

### **Characteristics of the Evidence Base**

Describe the number of studies identified, and the quality of them. Identify any serious issues with the studies (design/population/risk of bias/relevance of outcome measures etc) and provide a link to where the information on characteristics can be found in the main document.

Comment on the quality of the evidence base and the risk of bias associated with the key safety and effectiveness outcomes.

### Comparative Safety

Summarise the results of comparative safety presented in Section B of the SBA. Include a summary table from B.6, if relevant.

Identify the main adverse events (AEs).

Comment on whether there are clinically relevant differences in the reported harms, irrespective of whether the results are statistically significant. Note if there is a risk with use outside the immediate indication.

### Comparative Effectiveness

Summarise the comparative effectiveness information per key (or primary outcome) in the table below. The table can be copied for additional key patient-relevant outcomes but it would not be expected that more than two primary outcomes are presented. The meta-analysis is optional and will depend on the available evidence base. Results may alternatively be presented as a forest plot, if data from all table columns below are included or can be extracted from the forest plot.

Do not include results of secondary outcomes unless these are critical to the clinical claim or are used in the economic evaluation.

Comment on the results. Has the intervention met the trial requirements for superiority, equivalence, non-inferiority, etc? Note key issues discussed in Section B that may require the results to be interpreted with caution or that may invalidate the results (consider bulleting).

Table 3 Results of <key patient-relevant outcome> across the <studies/randomised controlled trials>

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Study ID | Risk of bias | Intervention<n with event/N (%)> <mean ± SD> | Comparator<n with event/N (%)> <mean ± SD> | Absolute difference<RD± NNT/NNH and 95% CI> <mean difference and SD or 95%CI> | Relative difference<OR/RR/HR and 95% CI> <results of statistical testing and p-value and/or 95% CI> |
| Trial 1 |  |  |  |  |  |
| Trial 2 |  |  |  |  |  |
| etc. |  |  |  |  |  |
| <Pooled result> |  | - | - | <XX> | <XX> |
| <Chi-square for heterogeneity: Q= , df= , *P=* | *I2* statistic with 95% uncertainty interval => | -  | -  | -  | -  |

<SD=standard deviation; RD=risk difference; NNT=number needed to treat; OR=odds ratio; RR=relative risk; HR=hazard ratio; NNH=number needed to harm.>

Select or add abbreviations as required.

If outcome is continuous, please provide the scale.

On the basis of the benefits and harms reported in the evidence base, the submission based assessment proposes that, relative to <the comparator>, <the intervention> has <superior/non-inferior/uncertain/inferior> safety and <superior/non-inferior/uncertain/inferior> effectiveness.

Comment on whether the clinical claim is reasonable and justify your view.

Comment on the balance of clinical benefit and harms associated with the proposed medical service.

If you think that the comparative effectiveness and safety sections above would be better summarised using the GRADE table in Section B.8 (and this table has been presented in the SBA), then you might consider presenting a combined ‘Benefits and Harms’ section in lieu of the comparative safety and effectiveness sections above. If you do this, then just present the paragraph of black text immediately above, your comments on whether the clinical claim has been met and the GRADE table.

### Translation Issues

Summarise the key translation issues addressed in the SBA. If the SBA has omitted an important translation issue, then identify it. If translation of the clinical evidence was not needed or not undertaken, please state this.

Do not include data and methods here.

Comment on the results of the pre-modelling studies, do they appropriately address the issues? Reference further discussion for complex items in Section C.

### Economic Evaluation

The economic evaluation is summarised in Table 4.

If an economic evaluation is not undertaken, check whether this has been justified with reference to Table D.1.2 of the *MSAC Therapeutic Guidelines* and do not insert the tables below into this section.

Table 4 Summary of the economic evaluation

|  |  |
| --- | --- |
| Perspective |  |
| Comparator |  |
| Type of economic evaluation | Eg. cost-effectiveness, cost-utility, cost-minimisation, cost-consequences. |
| Sources of evidence | Eg. Systematic review |
| Time horizon | Eg X years in the model base case |
| Outcomes | Eg. Name or list the outcome/s used in the model eg. LYG and QALYs |
| Methods used to generate results | E.g. trial-based, cohort expected value analysis, Markov model |
| <Health states> | Only put in this row, if it is relevant to your model |
| <Cycle length> | Only put in this row, if it is relevant to your model |
| Discount rate |  |
| Software packages used |  |

See Table D.3.1 in the *MSAC Therapeutic Guidelines*.

Comment briefly on the model, is it appropriate, are there any assumptions that have not been justified or may not be reasonable? Does it adequately represent reality?

<The overall costs and outcomes, and incremental costs and outcomes as calculated for the intervention and comparator in the model, and using the base case assumptions, are shown in the table below.> Choose which of Table 6 or 7/8 is appropriate for the evaluation that has been undertaken in the SBA. **Where you have re-calculated a number due to an error in the SBA then write the modified number in italics immediately below the calculation from the SBA (this would include the ICER).**

Table 5 <Title>

|  | **Cost** | **Incremental cost** | **Effectiveness (QALYs)** | **Incremental effectiveness** | **ICER** |
| --- | --- | --- | --- | --- | --- |
| <Intervention> |  |  |  |  |  |
| <Comparator> |  |  |  |  |  |

ICER = Incremental Cost Effectiveness Ratio>

<The results of a stepped analysis of the base case economic evaluation are given in the tables below.> **Where you have re-calculated a number due to an error in the SBA then write it in italics immediately below the calculation from the SBA**.

Table 6 Implications for the base case economic evaluation of applying the results of the clinical evaluation (Step 1 then Step 2)

|  |  |  |
| --- | --- | --- |
| Population and circumstances of use | As defined in trial(s) using ITT population | As defined by the requested restrictiona |
| Costs |  |  |
| Costs of therapy involving the proposed medical service | (Trial-based) | (Trial-based)b |
| Costs of therapy involving the main comparator | (Trial-based) | (Trial-based)b |
| Incremental costs | (Trial-based) | (Trial-based)b |
| For each trial-based outcome relied on in the economic evaluation before any extrapolation and/or transformation |  |  |
| Extent of outcomes with the proposed medical service |  |  |
| Extent of outcomes with the main comparator |  |  |
| Incremental effectiveness (with 95% CI) | (From Subsection B.6) | (From Subsection C.4) |
| **ICER** (cost/XXX) | XXX(Step 1) | XXX(Step 2) |

CI=confidence interval; ICER=incremental cost-effectiveness ratio; ITT=intention to treat >

**a** If there is no need to apply the results of the clinical evaluation, the data in this column should be identical to the data in the adjacent column reporting the incremental impacts using the results for the study/trial’s ITT population.

**b**Justify any variation in estimate of incremental costs from the trial-based costing.

Subsections refer to the *MSAC Therapeutic Guidelines*.

Table 7 Implications for the base case economic evaluation of extrapolating and transforming the results of the clinical evaluation (Step 3)

|  |  |  |  |
| --- | --- | --- | --- |
|  | Incremental costs | Incremental effectiveness | Incremental cost-effectiveness |
| For each trial-based outcome relied on in the economic evaluation without further modification | (From corresponding row of Step 2 in Table ES.5) | (From corresponding row of Step 2 in Table ES.5) | (From corresponding row of Step 2 in Table ES.5) |
| For any trial-based outcome relied on in the economic evaluation *with any* ***extrapolation*** *from the time horizon of the trial(s)* ***only*** | (Based on corresponding extrapolation of duration of treatment, if any) | (From Subsection C.4 if extrapolation is required) | (Alternative Step 3a) |
| For any important outcome generated for or by the economic evaluation from the trial-based outcome(s) (**‘transformation of nature of outcome’ only**) | (Include here any modelled increases in the provision of some resources and any modelled offsetting decreases of others) | (From Subsection C.4 if possible, or if this approach is used, explain why a presentation here is not possible) | (Alternative Step 3a) |
| For the final outcome relied on in the economic evaluation generated as a valuation of the trial-based outcome(s) (**‘value transformation’ only**) | (Should not change from Step 2 because nature of outcome does not change) | (From Subsection C.4 if possible, or if this approach is used, explain why a presentation here is not possible) | (Alternative Step 3a) |
| For the final outcome relied on in the economic evaluation ***combining*** *any extrapolation* from the time horizon of the trial(s) ***with*** *any transformation* of the trial-based outcome(s)  |  |  | (Completed Step 3 and expected base case)XXX(Step 3) |

>

Subsections refer to the *MSAC Therapeutic Guidelines*.

Comment on the ICER and whether it accurately represents the cost-effectiveness, in the evaluator’s judgment, of listing the intervention.

<The modelled results were most sensitive to >

Table 8 Key drivers of the economic model

| Description | Method/Value | Impact |
| --- | --- | --- |
| Eg Time horizon | 25 years; assumed from 6 month trial duration | High, favours intervention |
| Eg Upper 95% CL of the difference in outcomes | $100,000/QALY | High; favours comparator |
| etc |  |  |
|  |  |  |

<Other key areas of uncertainty were >

Did the sensitivity analysis cover all important aspects of the model? Is there a need for sensitivity analyses undertaken from a re-specified base case? Include important sensitivity analyses undertaken during the course of the evaluation.

Comment on the areas of uncertainty raised by sensitivity analyses.

### Estimated Extent of Use and Financial Implications

<An epidemiological approach has been used to estimate the financial implications of the introduction of <intervention>>

The financial implications to the MBS resulting from the proposed listing of <intervention> are summarised in Table 9. Where you have re-calculated a number due to an error in the SBA then write it in italics immediately below the calculation from the SBA.

Table 9 Total costs to the MBS associated with <intervention>

| **-** | **2015-16** | **2016-17** | **2017-18** | **2018-19** | **2019-20** |
| --- | --- | --- | --- | --- | --- |
| **<Intervention>** | **-** | **-** | **-** | **-** | **-** |
| Number of services |  |  |  |  |  |
| Sub-total cost |  |  |  |  |  |
| **<Any co-administered services currently MBS listed>** | **-** | **-** | **-** | **-** | **-** |
| Number of services  |  |  |  |  |  |
| Sub-total cost |  |  |  |  |  |
| **Total services** |  |  |  |  |  |
| **Total cost** |  |  |  |  |  |

The summary should primarily focus on the financial implications in terms of MBS rebates. If a service is primarily out-of-hospital, then there should be a separate analysis of the financial implications to the safety net in the SBA.

The ratio of in-hospital vs out-of-hospital service needs to be determined in the SBA’s analysis and the 75% vs 85% rebate (or if a GP service, 100% rebate), respectively, proportionately assigned in the costing. The Department is interested in the rebate as the input cost, not the schedule fee.

Provide an overall statement regarding the intervention cost per patient versus the cost of the comparator. Indicate whether the estimate in the SBA is reasonable or uncertain.

Provide an overall statement regarding how many patients are estimated to receive treatment and, if relevant, how many services per patient will be administered (pick a consistent time frame if needed). Indicate whether the estimate in the SBA is reasonable or uncertain.

Comment on the estimated net financial implications for the MBS in each year over five years – are the uncertain/over-estimated/under-estimated? Provide revised estimates if necessary.

<There is potential for the net cost/year to the MBS to be <greater/less> than estimated in the SBA.>

### Consumer impact summary

Summarise any feedback received during the public consultation period.

### <Other Relevant Considerations>

Are there specific matters relating to changes in the organisation of care, social/ethical/legal considerations, specific policy considerations, impact on consumers/patients, access/equity considerations, training/workforce considerations, risk share arrangements etc. that have not been mentioned in the SBA and will likely be important considerations for MSAC?

If these matters are mentioned in the SBA, are there any that require comment or amendment? Justify.

# Section A Context

The fundamental aim of this first section of the critique is to provide a summary and evaluation of the proposed context in which the intervention will be used.

A submission based assessment (SBA) requesting MBS listing of <insert name of intervention> for <insert description of patient population(s)> was received from <insert applicant’s name> by the Department of Health in <insert month & year SBA was received>.

## Items in the agreed PICO Confirmation

<This application is following a fit-for-purpose pathway, therefore a PICO Confirmation outlining the proposed use of <intervention> in Australian clinical practice was not <presented to/ratified by> the PICO Confirmation Advisory Sub-Committee (PASC).> If this is the case, then Table 10 below does not need to be inserted.

<A PICO Confirmation for MSAC Application <number> was approved by the PICO Confirmation Advisory Sub-Committee (PASC) of MSAC on <insert month, year>. A comparison of the consistency of this SBA with the PASC-approved PICO Confirmation is given in Table 10.>

If there was a PASC-approved PICO Confirmation then the checkbox below should be completed, providing a summary of whether the SBA has followed the PICO Confirmation. Has the approach suggested in the PICO Confirmation still been addressed but an alternative approach has also been presented? Or has the approach suggested in the PICO Confirmation not been addressed and only the alternative approach has been presented?

If the SBA has provided reasons as to why the PICO Confirmation was not followed, provide a very brief summary in the table of the justification for the change. If you wish to comment on whether the justification is reasonable, do so briefly (in italics – use the table text comment style provided) and expand below the table. If no justification is provided, indicate that the rationale was not given.

Table 10 PICO Confirmation checkbox

| PASC-approved PICO Confirmation Item | Compliance | Change and justification provided in SBA |
| --- | --- | --- |
| Proposed MBS listing | <Yes/No> |  |
| Population / clinical indication | <Yes/No> |  |
| Comparator | <Yes/No> |  |
| Clinical management algorithm | <Yes/No> |  |
| Clinical outcomes assessed | <Yes/No> |  |
| Healthcare resources | <Yes/No> |  |

Source: <Table/Figure, p/pp of SBA> <*Table constructed during the evaluation*>

NA=not applicable; PASC=PICO Advisory Sub-Committee

## Proposed Medical Service

Provide information about the proposed medical service and the mode of delivery.

Has MSAC previously considered an application requesting listing of this item and/or have any reviews relating to this intervention been conducted? If it has previously been considered, in a few sentences indicate the result of that consideration and main reason for the return of the proposal. What is different with the new SBA?

Is this a new intervention or an extension of a current intervention?

If the intervention is available as an interim funded item – provide dates of first review, short detail of the interim listing and when the interim funding is due to cease/required to be reviewed.

### <Marketing status of device / technology>

If the intervention does not require a new device but is instead a procedure or service, this section does not need to be completed. However, information on training/credentialing of service providers should still be critiqued in Section F.

All therapeutic products marketed in Australia require listing on the Australian Register of Therapeutic Goods (ARTG). MSAC will not consider a therapeutic product for reimbursement if the device is not listed on the ARTG. *Comment if there are any pre-requisites to implementation of any funding advice (eg. relevant ARTG numbers, etc) that have not been met.*

### <Other Indications>

<Mention whether the intervention is currently used for other clinical indications in Australia.>

### <Current funding arrangements>

<If relevant, comment on whether the intervention is currently delivered and funded by the public health sector (eg public hospitals) and whether an MBS item listing is likely to shift practice from the public health sector to the private health sector.>

## Proposal for Public Funding

Provide MBS or other public funding descriptors in the table below. Use the proposed item descriptor as set out in the SBA.

The proposed indication can be relatively short, e.g. severe rheumatoid arthritis.

The MBS item descriptor proposed in the SBA is given in Table 11.

Table 11 Proposed MBS item descriptor

|  |
| --- |
| Category <Insert proposed category no> – <INSERT CATEGORY NAME> |
| <Insert intervention name><Specify any restrictions on use e.g., patient characteristics to be satisfied, limits on frequency of use, limits on who can provide the item, or where it can be provided, etc><Specify any relevant explanatory notes> |
| Fee: <insert proposed MBS fee> |

Source: <Table/Figure>, <p/pp of the SBA>

Consider the proposed item descriptor in relation to what was in the PICO Confirmation (if one was provided to PASC) – is it the same, is it different? If the latter, then indicate the differences, discuss the rationale for them (if offered by the SBA) and comment on any implications.

Comment whether the item descriptor includes any restrictions to patients with specific clinical indications or due to prior interventions.

Compare the requested listing with other items that are listed on the MBS for the same patient group. If there is an inconsistency between the proposed listing(s) and listings for interventions already on the MBS, ask the MSAC to consider whether something should be included to maintain consistency between restrictions.

## Proposed population

Identify the main population(s) described in the PICO Confirmation including key inclusion and exclusion criteria.

Include a high level summary of the frequency (prevalence and/or incidence) of the population or disease in question and where relevant the natural history/pathophysiology of the condition of interest.

## Comparator Details

Brief description of the main comparator(s) described in the SBA.

Is the specified comparator the current practice that is most likely to be replaced or added to by the proposed medical service (refer to clinical management algorithm)? Is the comparator hospital based or MBS listed?

Comment if it is not the appropriate comparator and, in a sentence, state why – with reference to the PASC-ratified PICO Confirmation (if one was undertaken). Recommend an alternative comparator.

## Clinical management algorithm(s)

Comment on the proposed algorithm – is it realistic? Is it based on an evidence based or consensus-based clinical practice guideline?

Highlight the differences between the current and proposed algorithms e.g. change in positioning of a therapy in terms of lines of therapy; expansion/augmentation of the current management options; identification of patients who would now be treated who would previously not been treated.

* Provide a summary of how the proposed intervention is delivered in the clinical setting (e.g., details including amount to be delivered (if relevant), frequency of administration, where the delivery takes place etc)
* Identify any specialty groups who would perform the service delivering the intervention; and, if relevant, whether the proposed intervention should be restricted to any particular specialists or credentialed practitioners.
* State whether the proposed intervention would be delivered to a patient once or multiple times. Take into account any need to repeat the proposed intervention in particular circumstances, e.g., pathology tests may need to be repeated in the event of an inadequate sample.

Comment on any uncertainties (e.g., if the SBA assumes an intervention is used only once annually but the proposed item descriptor does not limit the frequency of use of the intervention).

Are there any limitations on how the intervention would be provided or the setting in which the intervention can be provided? Discuss with reference to Prerequisites below.

### Prerequisites

* Specify whether delivery/ordering of the intervention should be limited to a specific type of referrer or provider (e.g., specific qualifications or training or accreditation).
* Specify any requirements in terms of geography, facilities or location of delivery of service (e.g., limited to hospital setting or to approved laboratories; specification of any specific equipment or facilities that need to be available, prerequisites such as quality assurance or licensing requirements).
* If relevant, identify any required changes in capital equipment, and/or issues of location of the technology.
* If relevant, provide details of any quality assurance program that will apply to the proposed intervention.

### Co-administered and substituted interventions

The main co-administered <intervention is/interventions are> <list>.

* If relevant, summarise any interventions (including diagnostic and monitoring tests) that are required to be co-administered with the proposed intervention as part of a course of treatment (which may be before the delivery of the intervention, during the delivery of the intervention (e.g., drugs administered to minimise risk of or to manage adverse reactions), or following delivery of the intervention (e.g., pathology tests used in the monitoring of patients for outcome from the intervention).

Therapies likely to be prescribed less frequently are <list>.

* Identify interventions or therapies likely to be substituted by the proposed intervention, or used to manage adverse events associated with the proposed intervention.

Confirm that details provided for co-administered or substituted interventions are consistent with the relevant recommendations in relation to the use of the proposed intervention. Where the SBA claims that the intervention will substitute for another intervention, consider the potential for the proposed intervention to be used as an adjunct to the currently available therapies rather than as a substitute.

Confirm that all interventions and therapies are appropriately included in the economic evaluation. If any therapies are excluded from the economic evaluation, consider whether the SBA provides adequate justification for the exclusion. Reference the place in Section D where this is discussed in more detail.

## Key Differences in the Delivery of the Proposed Medical Service and the Main Comparator

Describe any differences in the delivery/organisation of care between the intervention and main comparator. If there are differences, then note the strengths and weaknesses of the different models of care.

## Clinical Claim

State the clinical claim proposed in the SBA. For example, the intervention has superior safety and effectiveness, relative to the main comparator. If a clinical claim is not provided in the SBA, this should also be stated.

## Summary of the PICO

The guiding framework of a PICO Confirmation is recommended by MSAC for each assessment. The PICO Confirmation describes current clinical practice and reflects the likely future practice with the proposed medical service. Provide a summary of the PICO.

If the PICO were not presented to PASC or the MSAC executive, comment on whether the PICO chosen are appropriate.

# Section B Clinical Evaluation

The fundamental aim of this section of the critique is to provide an assessment of the evidence presented in the SBA that demonstrates the comparative effectiveness and safety of the intervention versus the appropriate comparator. A lot of guidance on presentation of clinical evidence is provided in the MSAC Guidelines. Much information on the intent of each of the sections included in Section B can be found in those Guidelines so keep a set handy while you are doing an evaluation.

Also keep in mind the goal of providing clear, concise, plain English evaluation. Focus on the key issues and append sections where there are no major problems to discuss.

## Literature Sources and Search Strategies

The medical literature was searched on <Date> to identify relevant studies <and systematic reviews> published during the period <XXX to XXX>. Searches were conducted of the databases and sources described in <Appendix B> of the SBA. <Attempts were also made to source unpublished or grey literature from <XXX> >

Note - it is restrictive to search the literature by including search terms concerning the comparator and/or outcomes – however, in circumstances where the literature is very extensive this might be reasonable. The same applies to the use of study design filters. There needs to be good justification for the use of limits (eg publication year) and filters (eg study designs) in the search. There should be sufficient detail in the search strategy that it allows it to be replicated.

Comment on the thoroughness and currency of the literature search. Was it comprehensive? Was it consistent with the pre-specified PICO?

An independent search located <no other/several potentially> relevant <trials/studies>. Overall, the literature search is <un>satisfactory.

## Results of Literature Search

Comment on whether the stated process of study selection (eg number of reviewers) is open to bias. If the study selection process is not mentioned in the SBA, then state this.

Comment on whether a PRISMA flowchart has been provided, and whether it enables a clear understanding of how the evidence base was selected. If there is insufficient information provided to determine whether the study selection is consistent with the pre-specified study eligibility/inclusion criteria (with reference to the PICO), then state this.

Comment whether there are any contentious exclusions of trials/studies. Present in a way that MSAC can easily gauge the impact of the exclusion of these trials/studies.

If trials/studies that should have been included have been excluded, comment on the possible implications of including the omitted trials in the analysis.

### Appraisal of the evidence

Comment on whether a staged evidence appraisal process was used (see SBA/CA template).

## Risk of Bias Assessment

Has an appropriate method been used to determine the risk of bias associated with the findings presented in the SBA? Comment on whether the method used is likely to identify all of the potential areas where bias might have impacted on study findings eg in the design and execution of the studies/trials. Is the risk of bias assessment transparent and justifiable?

If a risk of bias assessment has not been performed, then provide an overview of the bias associated with the included studies using an appropriate method. The depth of this critical appraisal will depend on the number of trials and studies included in the SBA and the time available. Only concentrate on the key studies – those that are pivotal to the clinical claim. If you cannot provide a proper critical appraisal in the time available, state this.

Please note – if an indirect comparison is presented then the risk of bias assessment of the individual trials/studies would need to be supplemented with an assessment of the exchangeability of the study populations being compared – that is, the results for the common comparator arms should suggest that the populations are similar.

## Characteristics of the Evidence Base

A summary of the evidence used in the submission is provided in Table 12. A full description of the studies included to support the submission is given in Attachment B.

Comment on the quality of the evidence base and the risk of bias associated with the key safety and effectiveness outcomes.

Table 12 Key features of the included evidence comparing <intervention> with <comparator>

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Trial/Study | N | Design/ duration | Risk of bias | Patient population | Key outcome(s) | Result used in economic model |
| Jones 2010 | 225 | R, DB6 mths | Low |  | Mortality | Not used |
| Smith 2012 | 310 | R, OL3 mths | High |  | Response rate | Not used |
| Brown 2005 | 75 | CS, OL8 mths | Low |  | QoL | Not used |
| etc |  |  |  |  |  |  |
| etc |  |  |  |  |  |  |
| Meta-analysis | 410k= | - | - | <Fixed effect/random effect> model; <overall pooled> <and> <subgroup analyses> presented; heterogeneity analysis <key outcomes> analysed | - | Survival gain |

<CC=case control; Coh=cohort; CS=case series; DB=double blind; MC=multi-centre; NR=non-randomised; OL=open label (unblinded); QoL=quality of life; R=randomised; SB=single blind; X=cross-sectional..>

Select or add abbreviations as required.

Note – k=no. of studies included in meta-analysis. If the meta-analysis results are provided or relied upon in preference to the individual study results, then the individual studies do not need to be listed here – although they will need to be discussed in Section B.6.

Note – if you are relying on an indirect comparison, you will need to construct the table differently to indicate the common comparator and the two different trials or sets of trials that are being compared. Risk of bias in that situation must consider the exchangeability of the trial populations.

## Outcome Measures and Analysis

See Attachment B for details on the outcomes measured in the studies included in the SBA, along with the statistical methods used to analyse the results.

*If relevant, comment whether the outcomes extracted from the studies included in the SBA are consistent with those specified in the PICO Confirmation. If a PICO Confirmation was not provided to PASC, then comment on whether the outcomes chosen are clinically important and patient relevant.*

*Comment on whether the measurement of outcomes in the included studies was likely to be accurate; discuss the validity of the measurement tools used. Are the outcomes objectively or subjectively measured? (with the latter more prone to bias)*

*Make it clear how you are interpreting a clinically important effect for these outcomes and whether this differs from the interpretation used in the SBA. If a non-inferiority trial is used in the submission be sure to discuss the minimal clinically important difference (MCID) that is specified in the SBA and comment on whether this MCID is appropriate or not (and consistent with the literature).*

*Discuss whether the statistical analyses presented in the studies were pre-specified or post hoc, and the limitations associated with the latter. Only elaborate with a brief description of the statistical methodology if there is a problem, i.e. inappropriate statistical methodology has been used.*

## Results of the Systematic Literature review

## Comparative Safety

*Main Issues*

* *List the main safety issues that will impact on MSAC decision-making here. These should be consistent with the main issues summarised in the Executive Summary. If there are no safety issues, state this.*

Identify the main adverse events (AEs) associated with the proposed intervention (this should be consistent with the Harm Subheadings given below). Summarise the results of comparative safety presented in Section B of the SBA, with reference to table below.

### <Harm 1>

Table 13 Results of <key patient-relevant outcome> across the <studies/randomised controlled trials>

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Study ID | Risk of bias | Intervention<n with event/N (%)> <mean ± SD> | Comparator<n with event/N (%)> <mean ± SD> | Absolute difference<RD± NNT/NNH and 95% CI> <mean difference and SD or 95%CI> | Relative difference<OR/RR/HR and 95% CI> <results of statistical testing and p-value and/or 95% CI> |
| Trial 1 |  |  |  |  |  |
| Trial 2 |  |  |  |  |  |
| etc. |  |  |  |  |  |
| <Pooled result> |  | - | - | <XX> | <XX> |
| <Chi-square for heterogeneity: Q= , df= , *P=* | *I2* statistic with 95% uncertainty interval => | -  | -  | -  | -  |

Define abbreviations used in the table.

If outcome is continuous, please provide the scale.

Note – in table above SD=standard deviation; RD=risk difference; NNT=number needed to treat; OR=odds ratio; RR=relative risk; HR=hazard ratio; NNH=number needed to harm.

*Comment on the comparative safety, with particular reference to the patient-relevant outcomes specified in the PICO Confirmation (if presented to PASC). The emphasis should be on whether there are clinically relevant differences in the reported harms, irrespective of whether the results are statistically significant.*

### <Harm 2>

Same format as above.

Is the evidence base applicable to the populations/settings/circumstances of use in the Australian situation? (this should then be addressed in Section C of the SBA)

## Comparative Effectiveness

*Main Issues*

* *List the main issues regarding comparative effectiveness that will impact on MSAC decision-making here. These should be consistent with the main issues summarised in the Executive Summary. If there are no problems with the assessment of comparative effectiveness, then state this.*

Identify the key outcomes used to measure the comparative effectiveness of the proposed intervention (these should be consistent with the Subheadings given below).

### <Effectiveness Outcome 1>

Brief discussion of the evidence base reporting on this outcome, and the results found, with reference to table below.

The table can be copied for additional key patient-relevant outcomes but it would not be expected that more than three outcomes are presented. The meta-analysis is optional and will depend on the available evidence base. Results may alternatively be presented as a forest plot, if data from all table columns below are included or can be extracted from the forest plot.

Table 14 Results of <key patient-relevant outcome> across the <studies/randomised controlled trials>

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Study ID | Risk of bias | Intervention<n with event/N (%)> <mean ± SD> | Comparator<n with event/N (%)> <mean ± SD> | Absolute difference<RD± NNT/NNH and 95% CI> <mean difference and SD or 95%CI> | Relative difference<OR/RR/HR and 95% CI> <results of statistical testing and p-value and/or 95% CI> |
| Trial 1 |  |  |  |  |  |
| Trial 2 |  |  |  |  |  |
| etc. |  |  |  |  |  |
| <Pooled result> |  | - | - | <XX> | <XX> |
| <Chi-square for heterogeneity: Q= , df= , *P=* | *I2* statistic with 95% uncertainty interval => | -  | -  | -  | -  |

<SD=standard deviation; RD=risk difference; NNT=number needed to treat; OR=odds ratio; RR=relative risk; HR=hazard ratio; NNH=number needed to harm.>

Select or add abbreviations as required.

If outcome is continuous, please provide the scale.

*Comment on the comparative effectiveness, with particular reference to the patient-relevant outcomes specified in the PICO Confirmation (if presented to PASC). The emphasis should be on whether there are clinically relevant differences in the reported results between treatment arms ie statistical significance is important but not sufficient.*

### <Effectiveness Outcome 2>

Same format as above.

Is the evidence base applicable to the populations/settings/circumstances of use in the Australian situation? (this should then be addressed in Section C of the SBA)

## Extended Assessment of Comparative Harms

Highlight if there are any concerns raised by findings from post-market surveillance/unpublished data on harms. This might include data captured in administrative data sets, registry data, and recalls by regulatory agencies and from industry.

## Interpretation of the Clinical Evidence

On the basis of the benefits and harms reported in the evidence base, the submission based assessment proposes that, relative to <the comparator>, <the intervention> has <superior/non-inferior/uncertain/inferior> safety and <superior/non-inferior/uncertain/inferior> effectiveness.

Comment on whether the clinical claim is reasonable and justify your view.

Comment on the balance of clinical benefit and harms associated with the proposed medical service.

If a GRADE evidence profile has been provided, please reproduce here and critically discuss the findings and/or disagreements you may have with the conclusions that have been drawn.

Note – for a GRADE summary table, where a meta-analysis is not able to be done to arrive at a summary estimate of effect for each critical patient relevant outcome, it is suggested that the results from one or more of the better quality studies is presented and that the range of effects in these studies, with/without calculation of a median effect, is provided.

Please consult the paper by Guyatt et al 2013 (see reference list) for further information on interpreting GRADE summary tables. Please note, though, that the overall confidence in effect estimates ratings across outcomes (ie which would relate to the overall clinical claim in this instance) is usually based on the critical outcome that provides the lowest confidence in the effect estimates.

Please note that this table cannot be presented in web accessible format because of the necessity to have merged cells. It is therefore suggested that this is renamed as a figure and is copied and pasted into the report as a picture file (TIFF)

Table 15 Balance of clinical benefits and harms of <intervention>, relative to <comparator>, and as measured by the critical patient-relevant outcomes in the key studies

|  |  |  |  |
| --- | --- | --- | --- |
| **Quality assessment** | **No of patients** | **Effect** | **Qualitya** |
| **No of studies (k=)** | **Study Design/s** | **Risk of bias** | **Consistency of findings** | **Applicability (including indirectness)** | **Imprecision** | **Other considerations (eg publication bias)** | **Intervention**  | **Control** | **Relative(95% CI)** | **Absolute** |
| **Patient-relevant critical effectiveness outcome (eg from PICO in PICO Confirmation) <measured with tool (scale: XXX)/ follow-up at XX weeks>** |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Patient-relevant critical effectiveness outcome (eg from PICO in PICO Confirmation) <measured with tool (scale: XXX)/ follow-up at XX weeks >** |
|  |  |  |  |  |  |  |  |  |  |  |  |
| **Patient-relevant critical safety outcome (eg from PICO in PICO Confirmation) <measured with tool (scale: XXX)/ follow-up at XX weeks)>d** |
| 0 | - | - | - | - | - | none | - | - | - | - |  |
|

|  |
| --- |
| **Patient-relevant critical safety outcome (eg from PICO in PICO Confirmation) <measured with tool (scale: XXX)/ follow-up at XX weeks >** |

 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| a GRADE Working Group grades of evidence (Guyatt et al., 2013)**High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.**Very low quality:** We are very uncertain about the estimate. |

# Section C Translation Issues

This section should be used to highlight the shortcomings of the clinical data for the purposes of constructing an economic evaluation that appropriately captures all the issues. The premodelling studies then undertaken in Section C should in theory address these shortcomings.

Where **consistency, indirectness, applicability or other considerations have impacted on the confidence in the estimates (ie very low to moderate quality)** in Table 15 above, please indicate in sections below how the data have been translated for use in the economic model (if an economic model is produced).

If translation of the clinical evidence is not needed or not undertaken, please state this.

## Overview of Economic Evaluation and the Translation Issues that needed to be Addressed

It may be useful to briefly cover the form of the economic evaluation in order to provide context for the translation issues contained in Section C.

Try to keep this section very short and without excessive repetition from Section D.

If available in the SBA, it would make sense to outline the intentions of the applicant in creating an economic evaluation with the clinical information available.

Table 16 provides the translation issues as identified in the SBA.

Table 16 Translation issues identified in the submission based assessment

| Type | Issue |
| --- | --- |
| Applicability |  |
| Extrapolation |  |
| Transformation |  |
| Other |  |

Source: <Table/Figure>, <p/pp of the SBA>

As the table above demonstrates, the most important translation issues will generally be ones of applicability, extrapolation, and transformation.

Place the translation issues not identified in the SBA in Table 16 in italics. Detail will be provided below.

## Applicability translation issues

For example, with regard to Table 15 if **consistency** was poor (eg high heterogeneity in a meta-analysis), a subgroup analysis may be undertaken or referred to in Section C and then modelled in Section D. Example tables and approaches are suggested in the *MSAC Therapeutics Guidelines*.

If the **applicability** of the evidence to the target Australian population is poor, because the people participating in the studies (in the evidence base) were different, then Section C may require a description of the baseline risk in the Australian population which - in the model - can then be multiplied by the relative treatment effects reported in the evidence base.

If the **applicability** of the evidence is poor in terms of the healthcare context, then Section C would need to provide a list and unit costs of the healthcare resource usage likely in the Australian setting.

Comment on the results of the pre-modelling studies – are they reasonable? Are they accurate? Do they answer the proposed applicability question? Comment on any variation of treatment claim from Section B. Issues in this section are likely to be related to issues in D.2; avoid excessive repetition.

Provide detail on applicability issues NOT identified in the SBA but likely, in the evaluator’s judgement, to be critical for the decision.

## Extrapolation translation issues

Extrapolation issues arise whenever there is a need to extrapolate within-trial patterns (costs and effects) beyond the time horizon of the trial.

If the generalisability of the evidence to the Australian population is poor because the trial follow-up was not representative of the use of the intervention in practice (ie an “**other consideration**” in Table 15), then this is an Extrapolation Translation Issue according to the *MSAC Therapeutic Guidelines*.

Is the treatment effect assumed to be just as strong after five years or is a reduction of effect modelled?

With medical services each case will have to be examined individually with a view to what is the most likely trajectory of effect over time.

Comment on the results of the pre-modelling studies – are they reasonable? Are they accurate? Do they answer the proposed extrapolation question? Comment on any variation of treatment claim from Section B.

Provide detail on extrapolation issues NOT identified in the SBA but likely, in the evaluator’s judgement, to be critical for the decision.

## Transformation issues

If the evidence is **indirect** (eg the use of surrogate or intermediate outcomes) then this will require translation for use in the economic model eg transformation of the surrogate or intermediate outcomes in order to estimate clinically relevant outcomes such as QALYs.

Comment on the results of the pre-modelling studies – are they reasonable? Are they accurate? Do they answer the proposed transformation question? Comment on any variation of treatment claim from Section B.

Provide detail on transformation issues NOT identified in the SBA but likely, in the evaluator’s judgement, to be critical for the decision.

If data from the trials have been converted (e.g. from continuous to dichotomous or dichotomous to time-to-event outcomes) weigh up the additional uncertainty against the improved ease of interpretation of outcomes.

Markov models require probability over time (t) rather than rates. The SBA should transform from rate (r) to probability (P) and vice versa correctly (P = 1 - e-rt).

## Any other translation issues

## Relationship of each Pre-Modelling Study to the Economic Evaluation

Table 17 summarises the results of the premodelling studies presented in the SBA.

Table 17 Summary of results of pre-modelling studies and their uses in the economic evaluation

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Pre-modelling study | Results | Use in Section D | Cross-reference | Use in Subsection D.6 | Cross-reference |
| Applicability pre-modelling studies |
| Study 1 |  |  |  |  |  |
| Etc |  |  |  |  |  |
| Extrapolation pre-modelling studies |
| Study 2 |  |  |  |  |  |
| Etc |  |  |  |  |  |
| Transformation pre-modelling studies |
| Study 3 |  |  |  |  |  |
| Etc |  |  |  |  |  |
| Other translation pre-modelling studies |
| Study 4 |  |  |  |  |  |
| Etc |  |  |  |  |  |

Comment on key issues but only if there are important points re validity/value of results presented. The comment can be placed in italics in the table if very short otherwise place in paragraphs below the table but do not spend time repeating the issue. Summarise from the Section C.3 above.

# Section D Economic Evaluation

## Overview

The clinical evaluation suggests that, relative to <the comparator>, <the intervention> has <superior/non-inferior/uncertain/inferior> safety and <superior/non-inferior/uncertain/inferior> effectiveness <based on the evidence profile given in Table 15>. The appropriate economic analysis for the evaluation should therefore have been <refer to appropriate economic analysis in Table 18> (see Table 18). This <was/was not> provided in the submission based assessment

Table 18 Classification of the comparative effectiveness and safety of <the proposed therapeutic medical service> compared with <main comparator> and guide to the suitable type of economic evaluation

|  |  |
| --- | --- |
| Comparative safety | Comparative effectiveness |
| Inferior | Uncertaina | Non-inferiorb | Superior |
| Inferior | Health forgone: need other supportive factors | Health forgone possible: need other supportive factors | Health forgone: need other supportive factors | ? Likely CUA |
| Uncertaina | Health forgone possible: need other supportive factors | ? | ? | ? Likely CEA/CUA |
| Non-inferiorb | Health forgone: need other supportive factors | ? | CMA | CEA/CUA |
| Superior | ? Likely CUA | ? Likely CEA/CUA | CEA/CUA | CEA/CUA |

CEA=cost-effectiveness analysis; CMA=cost-minimisation analysis; CUA=cost-utility analysis

? = reflect uncertainties and any identified health trade-offs in the economic evaluation, as a minimum in a cost-consequences analysis

a ‘Uncertainty’ covers concepts such as inadequate minimisation of important sources of bias, lack of statistical significance in an underpowered trial, detecting clinically unimportant therapeutic differences, inconsistent results across trials, and trade-offs within the comparative effectiveness and/or the comparative safety considerations

b An adequate assessment of ‘non-inferiority’ is the preferred basis for demonstrating equivalence

An economic evaluation should be presented in all assessment reports to be considered by MSAC except when a service is indisputably demonstrated to be associated with net clinical harms to patients (as it is unlikely that MSAC will recommend government subsidy of the service).

The SBA presents <a trial-based economic evaluation, based on direct randomised trials only/a stepped economic evaluation, based on direct randomised trials and implementing a modelled evaluation using variables reported in Section C/a modelled economic evaluation based on an indirect comparison of <randomised/nonrandomised> studies>.

## Populations and settings

Comment on the demographic and patient characteristics of the population included in the economic evaluation. Are they appropriate to the proposed MBS listing? Justify. Refer to any analyses presented in Section B and C.3 to address the applicability of the population used in the model for the proposed restriction.

The population in the model is <not> representative of the population for whom MBS listing is sought.

## Structure and rationale of the economic evaluation

A summary of the key characteristics of the economic evaluation is given in Table 19.

Table 19 Summary of the economic evaluation

|  |  |
| --- | --- |
| Perspective |  |
| Comparator |  |
| Type of economic evaluation | EG. cost-effectiveness, cost-utility, cost-minimisation, cost-consequences. |
| Sources of evidence | Eg. Systematic review |
| Time horizon | Eg X years in the model base case |
| Outcomes | Eg. Name or list the outcome/s used in the model eg. LYG and QALYs |
| Methods used to generate results | E.g. trial-based, cohort expected value analysis, Markov model |
| <Health states> | Only put in this row, if it is relevant to your model |
| <Cycle length> | Only put in this row, if it is relevant to your model |
| Discount rate |  |
| Software packages used |  |

See Table D.3.1 in the *MSAC Therapeutic Guidelines*.

### Literature review

Comment whether a search of the literature was conducted by the applicant for published cost-effectiveness analyses of the proposed service. Is the approach suggested in the SBA consistent with other published economic evaluations on the topic? Are departures from the approaches in the literature justified?

### Structure of the economic evaluation

*Comment on whether the structure of the model is appropriate – does it accurately reflect the* *treatment algorithm for the use of the intervention?*

The description of the economic evaluation should include:

• a statement defining in detail the therapy options for which costs and outcomes are estimated in the economic evaluation

• a description of each of the types of event and health states possible in the economic evaluation, together with a justification of the selection of each health state for inclusion in the evaluation and a justification for those that were considered potentially suitable but that were excluded to avoid excessive complexity (if relevant)

• a description of the relationships and interactions between the various events and health states possible in the economic evaluation (including, where relevant for a state transition model, a detailed description of all possible transitions between the health states)

• a description of all assumptions made in the construction of the economic evaluation

• a decision tree diagram summarising the structure of the economic evaluation

#### Assumptions incorporated into the model structure:

*Have the economic evaluation characteristics summarised in Table 19 been appropriately justified? Comment and suggest/justify appropriate alternatives. For example,*

* *Comment on the appropriateness of the time horizon in terms of whether it accurately reflects the natural history of the medical condition, the clinical management algorithm and the time over which outcomes may occur. Is it long enough to capture important clinical events?*
* *Comment on whether the outcomes represent final outcomes and if so, how these have been translated from surrogate outcomes.*
* *Comment on whether the health states, cycle length and duration of time spent in health states are appropriate.*

## Inputs to the economic evaluation

### Costs

* *Discuss the appropriateness of any assumptions regarding the cost of the intervention such as the length and number of specialist visits required, costs of equipment use, co-interventions.*
* *Verify these costs and their use in the model. Check the model and locate the values if possible.*
* *Verify the sources are up to date and check the latest prices on the MBS and PBS.*
* *If costs have not been incorporated in the economic evaluation that ought to be, the evaluator can copy the health care resource items summary table provided in the SBA and add to it using italics. Comment below the table as to why these costs should not be omitted. Comment whether the SBA provides an appropriate justification for their exclusion. If possible a new base case in the economic evaluation may be developed using the new cost information. Reference this and the updated results.*
* *Consider the potential costs of adverse events if these are likely to differ between the intervention arm and the comparator arm of the model.*
* *Consider ongoing monitoring costs of patients. Do these differ between arms of the model?*

### Health outcomes

*Comment on the health outcomes used. Consider whether the variables that generate the incremental treatment effect are reasonable.*

* Describe the outcomes used in the economic evaluation, and reference (to Section C) any transformation or extrapolation of outcomes based on the clinical trials to outcomes used in the economic evaluation.
* Must include a statement about the treatment effect of the intervention, the source of the treatment effect from Sections B or C, the duration the model assumes the treatment effect will continue beyond the trial period (assuming that costs are not continuing).
* If the SBA provides a table highlighting the variables that generate the incremental treatment effect, then reproduce this table.

*Comment on whether the extrapolation of effect is reasonable given the length of trial data.*

*Comment on whether the assessment report assumes all patients receiving the intervention will experience the improved health outcomes? Is this reasonable?*

### Transition probabilities used in the economic evaluation

*Comment on the transition probabilities, focusing on whether they are reasonable. Do they accurately represent movement between health states? Do they reflect what is observed in the clinical evidence?*

* If the economic evaluation uses transition probabilities, provide them here in table form. If there are a large number of transition probabilities, include them in an attachment and reference them here.
* Identify temporary or absorbing health states.
* State the source of the transition probabilities and describe whether they are constant or change over model cycles.
* If probabilistic modelling is presented, include the type of probability distribution used and discuss its justification.
* Markov models require probability over time (t) rather than rates. Comment, if necessary, on whether the SBA has transform from rate (r) to probability (P) and vice versa correctly (P = 1 - e-rt).

### Utility/disutility values

*Comment on the utility values, focusing on the source and how the values were obtained (reference Section B or Section C if discussed there), and whether the values are reasonable.*

* List the utility values used in the economic evaluation in a table, along with their sources and cross-reference to Section B or Section C if discussed there.
* State whether they are trial-based or result from a translation issue in Section C (make a cross reference).
* Specify for how long the utility values are applied. This will be related to the length of time that patients spend in particular health states.
* If some utility or disutility values occur in one arm of the economic evaluation but not another then highlight this.

### Discount rate

*If a value different from 5% for both costs and outcomes is used, comment on the justification provided by the assessment report.*

* State if a discount rate is used in the economic evaluation and what value is used.
* Identify whether both costs and outcomes are discounted at the same annual rate.

## Results of the Economic Evaluation

Has the SBA presented the cost per patient per course if the proposed medical service is for acute or self-limited therapy, or the cost per patient per year if the proposed medical service is for chronic or continuing therapy?

Has the SBA presented the remaining results of the economic evaluation first in a disaggregated form, then in increasingly aggregated forms, using discounting as appropriate?

Has the SBA presented the appropriately aggregated and discounted results separately for outcomes and costs, and separately for the proposed medical service and its main comparator?

Has the SBA presented separate estimates of the incremental cost and the incremental effectiveness of substituting the proposed medical service for the main comparator?

For cost-effectiveness and cost-utility analyses, has the incremental cost-effectiveness ratio been presented as the incremental cost of achieving each extra unit of outcome with the proposed medical service substituted for the main comparator (the base case of the economic evaluation)?

*What is the impact of any departures from the suggested approaches above, in terms of confidence in the estimates provided in the economic evaluation in the SBA?*

Two different formats for presenting the findings of the economic evaluation are provided below. Choose which of these is appropriate for the evaluation that has been undertaken. Please delete the inappropriate one and/or incorporate additional summary information, as required.

### <Incremental costs and effectiveness

The overall costs and outcomes, and incremental costs and outcomes as calculated for the intervention and comparator in the model, with the base case assumptions, are shown in the table below. **Where you have re-calculated a number due to an error in the SBA then write the modified number in italics immediately below the calculation from the SBA (this would include the ICER).**

Table 20 <Title>

|  | **Cost** | **Incremental cost** | **Effectiveness (QALYs)** | **Incremental effectiveness** | **ICER** |
| --- | --- | --- | --- | --- | --- |
| <Intervention> |  |  |  |  |  |
| <Comparator> |  |  |  |  |  |

ICER = Incremental Cost Effectiveness Ratio>

### <Stepped economic evaluation

The results of a stepped analysis of the base case economic evaluation are given in the tables below. **Where you have re-calculated a number due to an error in the SBA then write it in italics immediately below the calculation from the SBA**.

<Table 21 Implications for the base case economic evaluation of applying the results of the clinical evaluation (Step 1 then Step 2)

|  |  |  |
| --- | --- | --- |
| Population and circumstances of use | As defined in trial(s) using ITT population | As defined by the requested restrictiona |
| Costs |  |  |
| Costs of therapy involving the proposed medical service | (Trial-based) | (Trial-based)b |
| Costs of therapy involving the main comparator | (Trial-based) | (Trial-based)b |
| Incremental costs | (Trial-based) | (Trial-based)b |
| For each trial-based outcome relied on in the economic evaluation before any extrapolation and/or transformation |  |  |
| Extent of outcomes with the proposed medical service |  |  |
| Extent of outcomes with the main comparator |  |  |
| Incremental effectiveness (with 95% CI) | (From Subsection B.6) | (From Subsection C.4) |
| **ICER** (cost/XXX) | XXX(Step 1) | XXX(Step 2) |

CI=confidence interval; ICER=incremental cost-effectiveness ratio; ITT=intention to treat >

**a** If there is no need to apply the results of the clinical evaluation, the data in this column should be identical to the data in the adjacent column reporting the incremental impacts using the results for the study/trial’s ITT population.

**b**Justify any variation in estimate of incremental costs from the trial-based costing.

Subsections refer to the *MSAC Therapeutic Guidelines*.

<Table 22 Implications for the base case economic evaluation of extrapolating and transforming the results of the clinical evaluation (Step 3)

|  |  |  |  |
| --- | --- | --- | --- |
|  | Incremental costs | Incremental effectiveness | Incremental cost-effectiveness |
| For each trial-based outcome relied on in the economic evaluation without further modification | (From corresponding row of Step 2 in Table ES.5) | (From corresponding row of Step 2 in Table ES.5) | (From corresponding row of Step 2 in Table ES.5) |
| For any trial-based outcome relied on in the economic evaluation *with any* ***extrapolation*** *from the time horizon of the trial(s)* ***only*** | (Based on corresponding extrapolation of duration of treatment, if any) | (From Subsection C.4 if extrapolation is required) | (Alternative Step 3a) |
| For any important outcome generated for or by the economic evaluation from the trial-based outcome(s) (**‘transformation of nature of outcome’ only**) | (Include here any modelled increases in the provision of some resources and any modelled offsetting decreases of others) | (From Subsection C.4 if possible, or if this approach is used, explain why a presentation here is not possible) | (Alternative Step 3a) |
| For the final outcome relied on in the economic evaluation generated as a valuation of the trial-based outcome(s) (**‘value transformation’ only**) | (Should not change from Step 2 because nature of outcome does not change) | (From Subsection C.4 if possible, or if this approach is used, explain why a presentation here is not possible) | (Alternative Step 3a) |
| For the final outcome relied on in the economic evaluation ***combining*** *any extrapolation* from the time horizon of the trial(s) ***with*** *any transformation* of the trial-based outcome(s)  |  |  | (Completed Step 3 and expected base case)XXX(Step 3) |

>

Subsections refer to the *MSAC Therapeutic Guidelines*.

Comment on the ICER and whether it accurately represents the cost-effectiveness, given the methodology used, of listing the intervention.

* Consider which step in the economic evaluation appears to contribute most to the final ICER.
* If the SBA presents Markov traces or other model traces, present those here.
* If the SBA has not presented model traces and they provide some insight into what is driving the model, then present them here and *comment*.
* *Comment on whether the model traces make sense – do they correspond to empirical data, or what would be expected with the disease or condition?*

## Sensitivity analyses

Has the SBA presented univariate (one-way) sensitivity analyses on all variables using plausible extremes of values, and justified the selection of those extreme values?

Has the SBA tabulated all univariate sensitivity analyses alongside the base case?

Has the SBA presented multivariate sensitivity analyses combining variables shown to be sensitive in the univariate analyses?

*What is the impact of any departures from the suggested approaches above, in terms of confidence in the estimates provided in the economic evaluation in the SBA?*

The modelled results were most sensitive to <list> (see Table 23).

Table 23 Key drivers of the economic model

| Description | Method/Value | Impact |
| --- | --- | --- |
| Eg Time horizon | 25 years; assumed from 6 month trial duration | High, favours intervention |
| Eg Upper 95% CL of the difference in outcomes | $100,000/QALY | High; favours comparator |
| etc |  |  |
|  |  |  |

*Comment on the appropriateness of the sensitivity analyses presented and the implications of these analyses in terms of the uncertainty in the modelled estimates.*

*Did the sensitivity analysis cover all important aspects of the model? Is there a need for sensitivity analyses undertaken from a re-specified base case?*

*Which sets of variable changes have the largest impact on the results? Is it realistic that these simultaneous changes could occur? If so, what is the impact on the ICER?*

# Section E Financial Implications

## Justification of the Selection of Sources of Data

Comment on the data sources used to estimate the financial impact of an MBS listing of the proposed medical service. Were the methods used appropriate? Discuss the limitations (including the representativeness of the results) and biases of the method adopted.

* In this section the applicant is required to demonstrate that they have obtained published or unpublished data appropriate to support estimates. Applicants may identify and use a variety of sources.
* Critically evaluate the sources presented for representativeness, applicability and reliability. Comment can be within a copy of the SBA’s table if short or otherwise presented in paragraphs below.
* Be pragmatic with comments recognising that the relevant data is often limited or not available and uncertainty will be inherent.
* Are there any other appropriate sources that have not been identified?

<An epidemiological approach has been used to estimate the financial implications of the introduction of <intervention>.>

## Use and Costs of <intervention>

### Eligible population for the requested restriction

List the assumptions or statements made in the SBA that are used to derive the estimates of eligible patients per year over a five year period.

State how these are supported by the source documents (E.1). References are important for the assumptions

Estimated number of eligible patients/year for <proposed intervention> in the SBA: <XXX>

<This estimate is likely to be reasonably accurate> <There is the potential for the number of eligible patients to be <greater/less> than this estimate.>

* Comment on the accuracy of the calculations and include corrections for arithmetic errors in italics in the table copied from the SBA (if relevant).
* Comment on whether the assumptions are reasonable and give reasons.
* State and comment on factors that contribute to any uncertainty around the number of eligible patients. These may include:
	+ Uncertainties in the assumptions used.
	+ Extent of clinical need in currently eligible population.
	+ Possibility that listing this intervention would change clinical management patterns.
	+ Consistency between the expected clinical management, model structure and inputs and methods for estimating the extent of use of the intervention.
	+ Potential for this intervention to ‘grow the market for treatment of this disease.

### Number of patients likely to use the intervention

State the how the SBA derived the number of eligible patients likely to use the intervention in each year (uptake rate) over five years.

Comment on how well this is justified or supported. Consider:

* Potential acceptance of the new intervention by clinicians, hospitals, specialists.
* Overseas guidelines -check NICE advice, CADTH, SMC.
* Applicability of clinical trials to the Australian population (Section C).
* Administration issues that affect uptake.
* Health system issues that would limit uptake.
* False positives resulting from a companion diagnostic test.

The estimate provided in the SBA of the number of patients/year likely to use <the intervention> is <reasonable/uncertain>.

A revised estimate of the number of patients/year likely to use <proposed intervention> undertaken during the evaluation is:

* This not obligatory but can be useful in exploring the impact of uncertainty on the estimates.
* The evaluator may be able to calculate another estimate, particularly in circumstances where the SBA chooses a prevalence rate at one extreme of the range in published literature. If there are a series of highly uncertain assumptions in place it may not be worth recalculating each step. Note that this may also be considered in sensitivity analysis later in Section E.
* With revised estimates, a brief justification of the more appropriate assumptions should be provided.

### <Number of services>

As the estimated number of patients may not correspond to how often an intervention is used (i.e. a service may be repeated) then it is necessary to provide an estimate of the number of services. If this number will not differ from the number of patients, then this does not need to be included.

The number of services associated with <intervention>, as estimated in the SBA, is:

State the how the SBA derived the number of services associated with the intervention in each year (uptake rate) over five years.

Comment on how well this is justified or supported. Consider:

* whether there is a difference between the estimate of the number of patients likely to be treated per year (above) and the number of services provided per patient. Discuss the reasons for the difference.
* presenting a table to set out the methods used to calculate the number of services.

The SBA’s estimate of the number of services per year is <reasonable/uncertain>.

* If uncertain summarise the main reasons but without repeating in extensive detail issues raised previously (uncertainties will flow through the calculations).
* Consider likely compliance and persistence, initiations and withdrawals through the year.

<There is the potential for the number of services to be <greater/less> than this estimate.>

A revised estimate of the number of services/year undertaken during the evaluation is:

* As above with the revision of patient numbers, this is not obligatory but can be useful in exploring the impact of uncertainty on the estimates.
* The evaluator may be able to calculate another estimate, particularly where there is a high level of uncertainty in the estimates of eligible patients or services/patient/year.
* Just write a sentence with the average co-payment per patient, no need to present tables for the co-payment.

## Changes in Use and Cost of Other Medical Services

Identify the other MBS-funded medical services that are likely to be affected by listing the proposed medical service.

For each proposed medical service, has the SBA estimated the extent of change in the number of times the proposed medical service is delivered each year over five years (disaggregated into proportions for the MBS and by beneficiary type)?

Comment on the approach taken, the estimates in the SBA, and provide some discussion of the implications. Example statements are provided below – please remember to provide justification for the statements.

* Does the approach correspond well with the economic evaluation presented in Section D? That is, the costs or cost-savings due to changes in services modelled in D should also feature here in a similar way. Raise the issue if this is not consistent.

<There is potential for the use of other MBS services to be <greater/less> than estimated in the SBA.>

<Other services that are likely to be substituted, but are not identified in the SBA, are <list>. >

* Provide revised estimates including the likely extent of substitution and cost implications of substitution for these services.

<Other services that are likely to be co-provided with listing of the proposed intervention, but that are not identified in the SBA, are <list>. >

* If included, provide revised estimates including the likely extent of provision and the cost implications for these services.
* Check with what the SBA has mentioned in Section A and ensure that this is treated consistently here in Section E.

## Financial Implications for the MBS

The financial implications to the MBS resulting from the proposed listing of <intervention> are summarised in Table 24. Where you have re-calculated a number due to an error in the SBA then write it in italics immediately below the calculation from the SBA.

Table 24 Total costs to the MBS associated with <intervention>

| **-** | **2015-16** | **2016-17** | **2017-18** | **2018-19** | **2019-20** |
| --- | --- | --- | --- | --- | --- |
| **<Intervention>** | **-** | **-** | **-** | **-** | **-** |
| Number of services |  |  |  |  |  |
| Sub-total cost |  |  |  |  |  |
| **<Any co-administered services currently MBS listed>** | **-** | **-** | **-** | **-** | **-** |
| Number of services  |  |  |  |  |  |
| Sub-total cost |  |  |  |  |  |
| **Total services** |  |  |  |  |  |
| **Total cost** |  |  |  |  |  |

The summary should primarily focus on the financial implications in terms of MBS rebates. If a service is primarily out-of-hospital, then there should be a separate analysis of the financial implications to the safety net in the SBA.

The ratio of in-hospital vs out-of-hospital service needs to be determined in the SBA’s analysis and the 75% vs 85% rebate (or if a GP service, 100% rebate), respectively, proportionately assigned in the costing. The Department is interested in the rebate as the input cost, not the schedule fee.

Comment on the estimated net financial implications for the MBS in each year over five years – are the uncertain/over-estimated/under-estimated? The cost offsets from Subsection E.3 should have been subtracted from the corresponding estimates calculated in Subsection E.2. Include these in the table above if helpful.

<There is potential for the net cost/year to the MBS to be <greater/less> than estimated in the SBA.>

### Potential usage outside the requested listing

* Critically evaluate the evidence base for possible use beyond the requested listing. This may not be relevant in many cases.
* Provide revised estimates if necessary.

## Financial Implications for Government Health Budgets

Comment on whether MBS listing of the proposed intervention is likely to have financial implications for other parts of the Australian Government’s health budget eg state and territory Government health budgets, including public hospitals.

### The Broader Impact on the MBS

The MBS includes a number of elements that applicants are not expected to estimate. This includes the cost of safety nets and incentives. Where possible, applicants should provide any additional information that will allow the Department to assess these factors.

### Other Government Impacts

Other Australian Government agencies are typically impacted by the implementation of new and amended medical services*.*

Comment, if relevant, on the estimated extent of the net change in the number of PBS prescriptions processed by Medicare Australia for payment (and, where appropriate, the net change in the number of authorisations by Medicare Australia) in each year over five years.

### State and Territory Government Health Budgets

Comment on any stated financial implications for state and territory Government health budgets, such as for public hospitals (including inpatient admissions, emergency department visits and outpatient clinic visits).

* There is controversy about valuing freed hospital resources in Government health budgets because, in the Australian public hospital system, the freed resources are typically redeployed to improve the health of the next available patient rather than being realised as financial cost reductions.

Is there any justification to support any claim for financial cost offsets from any reduction in the need to provide a public hospital resource? For example, is there a basis for concluding that the expected change is large enough that a resulting change in the provision of the resource would become a viable option for hospital management or other appropriate decision-makers?

*Comment on the estimated net financial implications for government health budgets in each year over five years.*

## Identification, Estimation and Reduction of Uncertainty

**E.4 and E.6 may be integrated, as needed, so the sensitivity analyses are presented immediately after the base calculations estimated in E.4.**

The SBA should identify the uncertainties, assess the extent and direction of these and make a statement about the impact on financial estimates.

Comment on the sensitivity analyses, focusing on whether they are appropriate and whether they provide reasonable estimates, particularly if the evaluation in E.2 – E.5 has highlighted uncertainties not considered in the SBA.

Provide the results of any sensitivity analyses of the financial implications presented by the SBA using tables as appropriate (include the base case financial implications for comparison). An example is provided below.

If the SBA has not provided any additional analyses, or there are important analyses that should be conducted, briefly describe them.

Table 25 Sensitivity analysis of the estimated net cost to the MBS

| EXAMPLE | 2012 | 2013 | 2014 | 2015 | 2016 |
| --- | --- | --- | --- | --- | --- |
| Overall net cost base case |  |  |  |  |  |
|  |  |  |  |  |  |
| Increased patient numbers |  |  |  |  |  |
|  |  |  |  |  |  |
| Increased services per patient |  |  |  |  |  |
|  |  |  |  |  |  |
| Reduced substitution |  |  |  |  |  |
|  |  |  |  |  |  |

Source: <Table/Figure>, <p/pp of the SBA>

# Section F Other relevant considerations

Are there specific matters relating to changes in the organisation of care, social/ethical/legal considerations, specific policy considerations, impact on consumers/patients, access/equity considerations, training/workforce considerations, risk share arrangements etc. that have not been mentioned in the SBA and will likely be important considerations for MSAC?

If these matters are mentioned in the SBA, are there any that require comment or amendment? Justify.

Discuss any key trials that are ongoing and due to report results shortly.

# References

Guyatt, G, Oxman, AD, Sultan, S, Brozek, J, Glasziou, P, Alonso-Coello, P, Atkins, D, Kunz, R, Montori, V, Jaeschke, R, Rind, D, Dahm, P, Akl, EA, Meerpohl, J, Vist, G, Berliner, E, Norris, S, Falck-Ytter, Y & Schunemann, HJ 2013, 'GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes', *J Clin Epidemiol*, vol. 66, no. 2, Feb, pp. 151-157.

# Attachment A

Additional information or tables relating to Section A should be included here.

# Attachment B

Additional information or tables relating to Section B should be included here.

| **Authors****Study ID****Publication Year** | **Study design/ duration** | **Level of evidencea and risk of bias assessmentb** | **Location****Setting****Length of follow-up** | **Study population characteristics****Eg N, age, gender, co-morbidities, disease description and severity, baseline function** | **Description of Intervention****<including duration of treatment>** | **Description of Comparator****<including duration of treatment>** | **Relevant outcomes assessed** **(ie related to outcomes specified in PICO)** | **Measurement of outcomes and methods of analysis** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| - |  |  |  |  |  |  |  |  |
| - |  |  |  |  |  |  |  |  |
| - |  |  |  |  |  |  |  |  |

# Attachment C

Additional information or tables relating to Section C should be included here.

# Attachment D

Additional information or tables relating to Section D should be included here.

# Attachment E

Additional information or tables relating to Section E should be included here.